A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia

Xiaohong Hao¹ | Mianmian Gu² | Jie Sun³ | Lin Cong⁴

¹Department of Hematology, Yantai YEDA Hospital, Yantai, China
²Department of Moral Education, Yantai Vocational College, Yantai, China
³Institute of Scientific and Technical Information of China, Beijing, China
⁴Department of Hematology, Yantaishan Hospital, Yantai, China

Correspondence
Lin Cong, Department of Hematology, Yantaishan Hospital, No.91 Jiefang Road, Yantai 264001, China.
Email: zoulan26177@163.com

Abstract
Background: This study aimed to explore the association of A-kinase interacting protein 1 (AKIP1) with chemokine (C-X-C motif) ligand (CXCL) 1/CXCL2, and further investigate their correlation with clinical features and prognosis in acute myeloid leukemia (AML) patients.

Methods: Totally 160 de novo AML patients were recruited, and their bone marrow samples were collected before treatment for detecting the expressions of AKIP1, CXCL1, and CXCL2 by the quantitative polymerase chain reaction. Complete remission (CR) was assessed after induction treatment, and event-free survival (EFS) and overall survival (OS) were calculated.

Results: AKIP1 expression was positively associated with CXCL1 ($P < .001$) and CXCL2 expression ($P < .001$). AKIP1 high expression was correlated with FAB classification ($P = .022$), monosomal karyotype ($P = .001$), and poor risk stratification ($P = .013$), while CXCL2 high expression was associated with monosomal karyotype ($P = .001$). As for treatment response, AKIP1 high expression exhibited a trend to be increased in non-CR patients compared with CR patients, while without statistical significance ($P = .105$). However, no correlation of CXCL1 ($P = .418$) or CXCL2 ($P = .685$) with CR achievement was observed. Most importantly, AKIP1 and CXCL1 were negatively correlated with accumulating EFS and OS (all $P < .05$), while CXCL2 only showed a trend to be negatively associated with accumulating EFS ($P = .069$) and OS ($P = .055$; but without statistical significance).

Conclusion: AKIP1 might serve as a novel biomarker for worse AML prognosis through the interaction of CXCL1/CXCL2.

Keywords
acute myeloid leukemia, AKIP1, complete remission, CXCL1, CXCL2
1 | INTRODUCTION

According to the most recent global statistics report, the incidence and mortality of leukemia account for 2.4% and 3.2% of all cancers, and acute myeloid leukemia (AML), as the most common acute leukemia, is characterized by the accumulation of immature and non-functional myeloid precursor cells in the blood and bone marrow. Current therapies, such as chemotherapy and allogeneic stem cell transplantation, bring in improvements to the survival rate in patients with AML, while the majority of patients with AML still experience unfavorable prognosis with below 50% 5-year overall survival (OS). Besides, patients with AML experience heterogeneous responses and outcomes to the treatments which make the exploration of markers for prognosis necessary. Therefore, it is essential to discover novel molecular markers which would serve as novel prognostic indexes and guide AML management in the future.

A-kinase interacting protein 1 (AKIP1), a molecular regulator of protein kinase A, is reported to serve as an adaptor or structural intracellular protein and is localized to the cytoplasm, nucleus, and mitochondria. Recent studies reveal that AKIP1 contributes to the tumorigenesis angiogenesis, lymph angiogenesis, and invasiveness in several solid tumors, including breast cancer, colorectal cancer, and gastric cancer, and it predicts worse survival profiles in patients with cancer, suggesting that AKIP1 functions as an oncogene and may be an effective prognostic marker in these cancers. Whereas in hematologic malignancies, the role of AKIP1 is limitedly studied. Interestingly, AKIP1 is shown to upregulate the expressions of the chemokine (C-X-C motif) ligand 1 (CXCL1)/chemokine (C-X-C motif) ligand 2 (CXCL2) and induce the activation of CXCL1/CXCL2 downstream oncogenic signaling pathway (Wnt/β-catenin signaling), leading to the development and progression of cervical cancer and hepatocellular carcinoma. Furthermore, previous reports illuminating that CXCL1 functions as pro-angiogenic gene in AML, and CXCL2 enhances survival of primary chronic lymphocytic leukemia cells, meanwhile, both of which possess prognostic value in leukemia. And Wnt signaling pathway is also shown to be an important oncogenic signaling functioning by regulating progression and chemosensitivity in AML. Collectively, we speculated that AKIP1 was positively associated with CXCL1/CXCL1, and they had potential to be prognostic biomarkers in patients with AML. Thus, we conducted this study to explore the association of AKIP1 with CXCL1/CXCL2 and further investigate their correlation with clinical features and prognosis in AML patients.

2 | METHODS

2.1 | Participants

A total of 160 de novo AML patients in our hospital were consecutively enrolled from May 2016 to April 2019. The inclusion criteria were as follows: (a) diagnosed as primary AML based on peripheral blood and bone marrow examinations including morphology, cytology, immunophenotyping, cytogenetics, and molecular genetics; (b) age above 18 years old; (c) no history of chemotherapy, radiotherapy, or other systematic treatments; (d) not complicated with other malignant myeloid diseases; and (e) negative serology for human immunodeficiency virus (HIV). And patients were excluded if they met the following criteria: (a) M3 in French-American-Britain (FAB) classification (acute promyelocytic leukemia); (b) life expectancy was <12 months. (c) unable to be followed up regularly; and (d) pregnant or lactating woman. This study was approved by the Ethics Committee of Yantaiashan Hospital, and all patients signed informed consents.

2.2 | Baseline data collection

Baseline characteristics of patients were collected after enrollment, which included (a) demographic characteristics: age and gender; (b) morphology classification (French-American-Britain [FAB] classification); (c) cytogenetic abnormalities: NK, CK, inv(16) or t(16;16), t(8;21), −7 or 7q−, +8, 11q23, t(9;11), −5 or 5q−, t(9;22), inv(3) or t(3;3) and t(6;9); (d) risk stratification; (e) karyotype (monosomal karyotype); and (f) molecular genetics variation: internal tandem duplications in the FMS-like tyrosine kinase 3 (FLT3-ITD) mutation, isolated biallelic CCAAT/enhancer-binding protein α (CEBPA) mutation, and nucleophosmin 1 (NPM1) mutation. FAB classification criterion was referred to a report of the FAB cooperative group, and risk stratification was performed according to NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (Version 1.2016).

2.3 | Samples collection and detection

Bone marrow samples of patients with AML were collected before initiation of treatment. Subsequently, the mononuclear cells were separated by density gradient centrifugation, then the expressions of AKIP1, CXCL1, and CXCL2 in mononuclear cells were detected by quantitative polymerase chain reaction (qPCR).

2.4 | Quantitative polymerase chain reaction

Total RNA was firstly extracted from bone marrow mononuclear cells using PureZOL RNA isolation reagent (Bio-Rad) and then reversely transcribed to cDNA using ReverTra Ace qPCR RT Kit (Toyobo) according to the instructions of the manufacturer. Following that, qPCR was performed using KOD SYBR qPCR Mix (Toyobo) to quantify AKIP1, CXCL1, and CXCL2 expressions. And the data were calculated using 2^−ΔΔt method with GAPDH as an internal reference, and the first enrolled AML patient as relative control for calculating. The primers used in RT-qPCR were listed as follows:

AKIP1 primer: forward GCCACACCTTAGGTCCCTTTC; reverse CGACTCGGCTCTGTGATAACG; CXCL1 primer: forward TGTCGTCTCTGTTCTGTGTA; reverse AGGATTGAGCCAAGTCTTTCC; CXCL2 primer: forward TCACCTCAAGAATCCCAAGGT; reverse AGACA AGCTTCTGCCCATT; and GAPDH primer: forward GAGTCCAC TGGCGTCTTCC; reverse ATCTGAGGCTGTGTCATCTCT. We searched the NCBI database to acquire the CDS sequences of AKIP1/
CXCL1/CXCL2 and designed the primers for AKIP1/CXCL1/CXCL2 via Primer Premier 6.0 (Premier, Canada).

2.5 | Treatment

All the patients with AML received appropriate induction treatments that were based on their physical condition, clinical status, and willingness, according to AML guideline. Complete remission (CR) was assessed for patients with AML after induction treatment, and CR was defined as bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0 × 10^9/L (1000/μL), platelet count >100 × 10^9/L (100 000/μL), and independence of red cell transfusions. Then, hematopoietic stem cell transplantation (HSCT) was performed in CR patients with suitable bone marrow donors.

2.6 | Follow-up

Regular follow-up was performed by telephone or clinic visit, the last follow-up date was April 30, 2019, and the median follow-up duration was 17.5 months ranging from 2.0 to 36.0 months. Event-free survival (EFS) was measured from the date of entry into the study to the date of induction treatment failure, or relapse from CR or death, and patients without any of these events were censored on the date they were last examined. Overall survival (OS) was measured from the date of entry into the study to the date of death, and patients not known to have died at last follow-up were censored on the date they were last known to be alive.

2.7 | Statistical analysis

Statistical analysis was performed using SPSS 24.0 software (IBM), and figures were plotted using GraphPad Prism 7.00 software (GraphPad Software). Categorical variables were summarized using frequency and percentage, while continuous variables were displayed as mean ± standard deviation (SD) or median and interquartile range (IQR). Chi-square test was used to determine the correlation between categorical variables, and Spearman’s rank correlation test was used to examine the correlation between continuous variables. Kaplan-Meier curve was used to display OS and EFS, and the log-rank test was used to compare the difference of EFS and OS between groups. All tests were two-tailed, and P value <.05 was considered significant.

3 | RESULTS

3.1 | Baseline characteristics

There were totally 160 AML patients with the mean age of 45.7 ± 13.3 years included in the present study (Table 1). Among them, 84 (52.5%) were males and 76 (47.5%) were females. The median WBC was 17.5 (8.7-32.2) × 10^9/L. Regarding the FAB classification, there were 1 (0.6%), 58 (36.3%), 43 (26.9%), 45 (28.1%), and 13 (8.1%) patients in M1, M2, M4, M5, and M6, respectively. Other detailed baseline characteristics were listed in Table 1.

3.2 | Correlation of AKIP1 with CXCL1 and CXCL2

AKIP1 relative expression was observed to be positively associated with CXCL1 relative expression (r = 0.409, P < .001; Figure 1A) and CXCL2
Relative expression ($r = 0.356$, $P < .001$; Figure 1B) in patients with AML. AKIP1/CXCL1/CXCL2 relative expressions were shown in Figure 1C.

### 3.3 | Correlation of AKIP1, CXCL1, and CXCL2 with clinical characteristics

According to the median level of AKIP1, CXCL1, or CXCL2, these indexes were divided into high and low expressions (Table 2). AKIP1 high expression was correlated with FAB classification ($P = .022$), positively associated with MK ($P = .001$), poor risk stratification ($P = .013$), while there was no correlation between AKIP1 expression with age, gender, WBC, cytogentic, FLT3-ITD mutation, isolated biallelic CEBPA mutation, or NPM1 mutation (all $P > .05$). As for CXCL1 expression, no association was found between CXCL1 expression with age, gender, WBC, FAB classification, cytogentic, MK, FLT3-ITD mutation, isolated biallelic CEBPA mutation, NPM1 mutation, or risk stratification (all $P > .05$). With regarding to CXCL2 expression, its high expression was associated with MK ($P = .001$), however, there was no association between CXCL2 expression with age, gender, WBC, FAB classification, cytogentic, FLT3-ITD mutation, NPM1 mutation, isolated biallelic CEBPS mutation, or risk stratification (all $P > .05$).

### 3.6 | Correlation of accumulating OS with AKIP1, CXCL1, and CXCL2

Accumulating OS was reduced in AML patients with AKIP1 high expression compared with those with AKIP1 low expression ($P < .001$; Figure 3A). And accumulating OS was decreased in AML patients with CXCL1 high expression compared with those with CXCL1 low expression ($P = .011$; Figure 3B). While accumulating OS was similar between in AML patients with CXCL2 high expression and those with CXCL2 low expression ($P = .055$; Figure 3C).

### 4 | DISCUSSION

In this present study, we observed that (a) AKIP1 expression was positively associated with CXCL1 and CXCL2 expression, and AKIP1 high expression was correlated with FAB classification, MK as well as poor risk stratification, and CXCL2 high expression was associated with MK in AML patients. (b) AKIP1 and CXCL1 were negatively correlated with accumulating EFS and accumulating OS in AML patients.

Accumulating researches indicate that AKIP1 dysregulation is associated with pathological conditions, and AKIP1 participates in the development and progression of various types of solid tumors.\(^5\) For example, clinical experiments in patients with gastric cancer illustrate that AKIP1 high expression correlates with advanced TNM stage and lymph node metastasis, and mechanistic experiments exhibit that AKIP1 promotes gastric cancer cell proliferation, migration, and invasion by activating slug-induced EMT.\(^5\) Another study displays that increased AKIP1 expression is associated with early
| Items                          | AKIP1 expression |                  |                  |                  |                  |
|-------------------------------|------------------|------------------|------------------|------------------|------------------|
|                               | High             | Low              | P value          | High             | Low              | P value          |
|                               |                  |                  |                  |                  |                  |
| Age, No. (%)                  |                  |                  |                  |                  |                  |
| <45 y                         | 40 (51.9)        | 37 (48.1)        | 0.635            | 41 (53.2)        | 36 (46.8)        | 0.429            |
| ≥45 y                         | 40 (48.2)        | 43 (51.8)        |                  | 39 (47.0)        | 44 (53.0)        |                  |
| Gender, No. (%)               |                  |                  |                  |                  |                  |
| Male                          | 42 (50.0)        | 42 (50.0)        | 1.000            | 42 (50.0)        | 42 (50.0)        | 1.000            |
| Female                        | 38 (50.0)        | 38 (50.0)        |                  | 38 (50.0)        | 38 (50.0)        |                  |
| WBC, No. (%)                  |                  |                  |                  |                  |                  |
| <10 × 10^9/L                  | 21 (45.7)        | 25 (54.3)        | 0.485            | 23 (50.0)        | 23 (50.0)        | 1.000            |
| ≥10 × 10^9/L                  | 59 (51.8)        | 55 (48.2)        |                  | 57 (50.0)        | 57 (50.0)        |                  |
| FAB classification, No. (%)   |                  |                  |                  |                  |                  |
| M1                            | 0 (0.0)          | 1 (100.0)        | 0.022            | 1 (100.0)        | 0 (0.0)          | 0.078            |
| M2                            | 20 (34.5)        | 38 (65.5)        |                  | 22 (37.9)        | 36 (62.1)        |                  |
| M4                            | 28 (65.1)        | 15 (34.9)        |                  | 28 (65.1)        | 15 (34.9)        |                  |
| M5                            | 24 (53.3)        | 21 (46.7)        |                  | 22 (48.9)        | 23 (51.1)        |                  |
| M6                            | 8 (61.5)         | 5 (38.5)         |                  | 7 (53.8)         | 6 (46.2)         |                  |
| Cytogenetics, No. (%)         |                  |                  |                  |                  |                  |
| +t(16) or +t(16;16)           | 6 (60.0)         | 4 (40.0)         | 0.121            | 3 (30.0)         | 7 (70.0)         | 0.552            |
| +8                            | 3 (50.0)         | 3 (50.0)         |                  | 3 (50.0)         | 3 (50.0)         |                  |
| +t(9;11)                      | 1 (33.3)         | 2 (66.7)         |                  | 2 (66.7)         | 1 (33.3)         |                  |
| NK                            | 37 (47.4)        | 41 (52.6)        |                  | 41 (52.6)        | 37 (47.4)        |                  |
| −7 or 7q−                     | 5 (71.4)         | 2 (28.6)         |                  | 2 (28.6)         | 5 (71.4)         |                  |
| +11q23                        | 1 (20.0)         | 4 (80.0)         |                  | 1 (20.0)         | 4 (80.0)         |                  |
| −5 or 5q−                     | 1 (100.0)        | 0 (0.0)          |                  | 1 (100.0)        | 0 (0.0)          |                  |
| +t(9;22)                      | 0 (0.0)          | 1 (100.0)        |                  | 1 (100.0)        | 0 (0.0)          |                  |
| +inv(3) or +t(3;3)            | 1 (100.0)        | 0 (0.0)          |                  | 1 (100.0)        | 0 (0.0)          |                  |
| +t(6;9)                       | 0 (0.0)          | 1 (100.0)        |                  | 0 (0.0)          | 1 (100.0)        |                  |
| Others (non-defined)          | 11 (57.9)        | 8 (42.1)         |                  | 12 (63.2)        | 7 (36.8)         |                  |
| MK, No. (%)                   |                  |                  |                  |                  |                  |
| No                            | 65 (45.5)        | 78 (54.5)        | 0.001            | 12 (70.6)        | 5 (29.4)         | 0.073            |
| Yes                           | 15 (88.2)        | 2 (11.8)         |                  | 68 (47.6)        | 75 (52.4)        |                  |
| FLT3-ITD mutation, No. (%)    |                  |                  |                  |                  |                  |
| No                            | 58 (47.2)        | 65 (52.8)        | 0.189            | 60 (48.8)        | 63 (51.2)        | 0.574            |
| Yes                           | 22 (59.5)        | 15 (40.5)        |                  | 20 (54.1)        | 17 (45.9)        |                  |
| Isolated biallelic CEBPA mutation, No. (%) |                |                  |                  |                  |                  |
| No                            | 72 (49.3)        | 74 (50.7)        | 0.576            | 73 (50.0)        | 73 (50.0)        | 1.000            |
| Yes                           | 8 (57.1)         | 6 (42.9)         |                  | 7 (50.0)         | 7 (50.0)         |                  |
| NPM1 mutation, No. (%)        |                  |                  |                  |                  |                  |
| No                            | 54 (50.5)        | 53 (49.5)        | 0.867            | 54 (50.5)        | 53 (49.5)        | 0.867            |
| Yes                           | 26 (49.1)        | 27 (50.9)        |                  | 26 (49.1)        | 27 (50.9)        |                  |
| Risk stratification, No. (%)  |                  |                  |                  |                  |                  |
| Favorable                     | 13 (33.3)        | 26 (66.7)        | 0.013            | 15 (38.5)        | 24 (61.5)        | 0.252            |
| (Continues)
recurrence and AKIP1 is a potential mediator of tumor metastasis via regulating Wnt/β-catenin signaling in hepatocellular carcinoma.7 Furthermore, Wnt/β-catenin signaling, as an oncogenic signaling in both solid tumors and hematologic malignancies, is reported to be associated with the AML-related fusion proteins and FLT3-ITD mutation, which correlated with unfavorable survival profiles in AML patients.15 Nevertheless, the role of AKIP1 in hematologic malignancies has been rarely investigated. In addition, recent studies illustrate that CXCL1 and CXCL2 are activated by AKIP1 during the oncogenic development, and CXCL1/CXCL2 regulate AML cell migration during the leukemogenesis.8,9,16 Accordingly, we hypothesized that AKIP1 might be correlated with clinical outcomes via reaction with CXCL1/ CXCL2 in AML patients. In the present study, we found that AKIP1 expression was positively associated with both CXCL1 and CXCL2 expressions, and AKIP1 high expression was correlated with FAB classification, MK as well as poor risk stratification, and CXCL2 high expression was associated with MK in AML patients. The possible reasons might include that (a) increased AKIP1 expression might

### TABLE 3

| Items                      | AKIP1 expression | CXCL1 expression | CXCL2 expression |
|----------------------------|------------------|------------------|------------------|
|                            | High Low P value | High Low P value | High Low P value |
| CR, No. (%)                |                  |                  |                  |
| No                         | 19 (63.3) 11 (36.7) 0.105 | 17 (56.7) 13 (43.3) 0.418 | 14 (46.7) 16 (53.3) 0.685 |
| Yes                        | 61 (46.9) 69 (53.1) | 63 (48.5) 67 (51.5) | 66 (50.8) 64 (49.2) |
| Allo-HSCT post-CR, No. (%) |                  |                  |                  |
| No                         | 53 (45.7) 63 (54.3) 0.417 | 58 (50.0) 58 (50.0) 1.000 | 56 (48.3) 60 (51.7) 0.258 |
| Yes                        | 8 (57.1) 6 (42.9) | 7 (50.0) 7 (50.0) | 9 (64.3) 5 (35.7) |

Note: Correlation was determined by Chi-square test. Abbreviations: AKIP1, A-kinase interacting protein 1; allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete response; CXCL1, chemokine (C-X-C motif) ligand 1; CXCL2, chemokine (C-X-C motif) ligand 2; FAB, French-American-British classification; FLT3-ITD, internal tandem duplications in the FMS-like tyrosine kinase 3; MK, monosomal karyotype; WBC, white blood cell.
enhance the level of CXCL1/CXCL2, which promoted AML cell proliferation and migration, further contributing to the progression of AML and the chromosome abnormality. (b) Upregulated AKIP1 might activate the oncogenic CXCL1/CXCL2 downstream signaling pathway (Wnt/β-catenin signaling), leading to increased AML-related genes mutations, which further contributed to poor risk stratification. Conversely, overexpression of CXCL1/CXCL2 might also activate the oncogenic pathway, which increased the expression of AKIP1, while the underlying mechanism needed further exploration via cellular experiments.

Recent studies reveal that AKIP1 has potential to be a prognostic marker in several solid cancers. For example, AKIP1 serves as a mediator of tumor metastasis, and its high expression is correlated with unfavorable prognosis in patients with non-small cell lung cancer. In another study AKIP1 is an independent predictive factor for decreased accumulating OS in patients with colorectal cancer. As for CXCL1/CXCL2 are found to be of prognostic value in various cancers including hematologic malignancies, and their involvements in leukemia have been illustrated by several studies. CXCL1 downregulation is correlated with increased cell apoptosis and inhibited cell proliferation in AML, and CXCL2 overexpression is exhibited to enhance chronic lymphocytic leukemia cell survival. Given the previous studies, we speculated that AKIP1/CXCL1/CXCL2 might associate with unfavorable prognosis in patients with AML. In the study, AKIP1 and CXCL1 were negatively correlated with accumulating EFS and accumulating OS in AML patients. The possible explanations might consist of that (a) based on our previous data, AKIP1 high expression was correlated with unfavorable cytogenetic change (such as: MK occurrence) and poor risk stratification, which indirectly led to poor prognosis. (b) AKIP1 high expression might activate CXCL1/CXCL2 downstream oncogenic signaling pathway (such as: Wnt/β-catenin signaling), which further promoted the self-renewal of AML stem cell and enhanced the resistance to the chemotherapy; therefore, patient with AKIP1 high expression had poor survival profiles in a long-term period.

However, there were still several limitations in our study as follows: (a) The follow-up duration was relatively short; thus, the long-term prognostic value of AKIP1/CXCL1/CXCL2 needed to be observed in a longer follow-up. (b) Considering that the underlying molecular mechanism was not evaluated in the present study, further cellular experiments were needed in the future. (c) The sample size was relatively small; thus, more patients from multiple regions throughout China were needed for validation. (d) Although AKIP1 expression was found to be positively associated with CXCL1/CXCL2 expression, the detailed regulatory mechanism of AKIP1/ CXCL1/ CXCL2 signaling needed further cellular experiments for exploration.

In conclusion, AKIP1 might serve as a novel biomarker for worse AML prognosis through the interaction of CXCL1/CXCL2.

ACKNOWLEDGMENTS
None.

CONFLICT OF INTEREST
The authors declare no competing interests.

ORCID
Lin Cong https://orcid.org/0000-0002-4111-0690

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
3. Isidori A, Loscocco F, Curti A, Amadori S, Visani G. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 2019;20(7):467-470.
4. Sastri M, Barraclough DM, Carmichael PT, Taylor SS. A-kinase-interacting protein localizes protein kinase A in the nucleus. *Proc Natl Acad Sci U S A.* 2005;102(2):349-354.

5. Chen D, Cao G, Liu Q. A-kinase-interacting protein 1 facilitates growth and metastasis of gastric cancer cells via Slug-induced epithelial-mesenchymal transition. *J Cell Mol Med.* 2019;23(6):4434-4442.

6. Jiang W, Yang W, Yuan L, Liu F. Upregulation of AKIP1 contributes to metastasis and progression and predicts poor prognosis of patients with colorectal cancer. *Onco Targets Ther.* 2018;11:6795-6801.

7. Cui Y, Wu X, Lin C, et al. AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/beta-catenin/CBP signaling pathway. *Oncogene.* 2019;38(27):5516-5529.

8. Zhang W, Wu Q, Wang C, Yang L, Liu P, Ma C. AKIP1 promotes angiogenesis and tumor growth by upregulating CXC-chemokines in cervical cancer cells. *Mol Cell Biochem.* 2018;448(1–2):311-320.

9. Ferretti E, Di Carlo E, Cocco C, et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. *Immunol Lett.* 2010;133(2):99-105.

10. Burgess M, Cheung C, Chambers L, et al. CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. *Leuk Lymphoma.* 2012;53(10):1988-1998.

11. Yang S, Gu Y, Wang G, et al. HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/beta-catenin signaling. *Int J Mol Med.* 2019;44(2):427-436.

12. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. *Ann Intern Med.* 1985;103(4):620-625.

13. NCCN clinical practice guidelines in oncology: acute myeloid leukemia (Version 1.2016). https://www.nccn.org

14. Doehner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood.* 2010;115(3):453-474.

15. Kuhn K, Cott C, Bohler S, et al. The interplay of autophagy and beta-Catenin signaling regulates differentiation in acute myeloid leukemia. *Cell Death Discov.* 2015;1:15031.

16. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. *Curr Top Microbiol Immunol.* 2010;341:149-172.

17. Mo D, Li X, Li C, et al. Overexpression of AKIP1 predicts poor prognosis of patients with breast carcinoma and promotes cancer metastasis through Akt/GSK-3beta/Snail pathway. *Am J Transl Res.* 2016;8(11):4951-4959.

18. Guo X, Zhao L, Cheng D, Mu Q, Kuang H, Feng K. AKIP1 promoted epithelial-mesenchymal transition of non-small-cell lung cancer via transactivating ZEB1. *Am J Cancer Res.* 2017;7(11):2234-2244.

19. Wang L, Zhang C, Xu J, et al. CXCL1 gene silencing inhibits HGC803 cell migration and invasion and acts as an independent prognostic factor for poor survival in gastric cancer. *Mol Med Rep.* 2016;14(5):4673-4679.

20. Leung G, Zhang C, Ng N, et al. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. *Am J Hematol.* 2019;94(6):650-657.

21. Canaani J, Labopin M, Itala-Remes M, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. *Leukemia.* 2019;33(8):1944-1952.

How to cite this article: Hao X, Gu M, Sun J, Cong L. A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia. *J Clin Lab Anal.* 2020;34:e23052. [https://doi.org/10.1002/jcla.23052](https://doi.org/10.1002/jcla.23052)